Product Description: Delcasertib (KAI-9803) is a potent and selective δ-protein kinase C (δPKC) inhibitor. Delcasertib (KAI-9803) could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI)[1][2].
Applications: COVID-19-immunoregulation
Formula: C120H199N45O34S2
References: [1]Miyaji Y, et al. Distribution of KAI-9803, a novel δ-protein kinase C inhibitor, after intravenous administration to rats. Drug Metab Dispos. 2011 Oct;39(10):1946-53./[2]Bates E, et al. Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation. 2008 Feb 19;117(7):886-96.
CAS Number: 949100-39-4
Molecular Weight: 2880.28
Compound Purity: 98.21
Research Area: Inflammation/Immunology; Cardiovascular Disease
Solubility: DMSO : ≥ 100 mg/mL
Target: PKC
English
Deutsch
